Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TNXP > SEC Filings for TNXP > Form 8-K on 17-Oct-2013All Recent SEC Filings

Show all filings for TONIX PHARMACEUTICALS HOLDING CORP. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for TONIX PHARMACEUTICALS HOLDING CORP.


17-Oct-2013

Change in Directors or Principal Officers, Financial Statemen


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Lederman & Co., LLC

Effective October 15, 2013, Tonix Pharmaceuticals Holding Corp. (the "Company") entered into an amendment to the consulting agreement (the "Lederman Amendment") with Lederman & Co., LLC ("Lederman"), which amended the consulting agreement entered into with Lederman on June 4, 2010, as amended on December 9, 2010 and February 1, 2012 (the "Lederman Agreement"), pursuant to which Seth Lederman serves as our President and Chief Executive Officer. Pursuant to the Lederman Amendment, the annual compensation under the Lederman Agreement was increased from $250,000 to $325,000. In addition, on October 15, 2013, the board of directors of the Company (the "Board") granted a bonus of $115,000 to Dr. Lederman.

Leland Gershell

Effective October 15, 2013, the Company entered into an amendment to the employment agreement (the "Gershell Amendment") with Leland Gershell, which amended the employment agreement entered into with Dr. Gershell on April 1, 2012 (the "Gershell Agreement"), pursuant to which Dr. Gershell serves as our Chief Financial Officer. Pursuant to the Gershell Amendment, the annual salary under the Gershell Agreement was increased from $175,000 to $225,000. In addition, on October 15, 2013, the Board granted a bonus of $50,000 to Dr. Gershell.

Bruce Daugherty

Effective October 15, 2013, the Company entered into an amendment to the employment agreement (the "Daugherty Amendment") with Bruce Daugherty, which amended the employment agreement entered into with Dr. Daugherty on April 1, 2012 (the "Daugherty Agreement"), pursuant to which Dr. Daugherty serves as our Senior Director of Drug Development. Pursuant to the Daugherty Amendment, the annual salary under the Daugherty Agreement was increased from $140,000 to $190,000. In addition, on October 15, 2013, the Board granted a bonus of $40,000 to Dr. Daugherty.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

10.01   Amendment to Consulting Agreement, between Tonix Pharmaceuticals, Inc.
        and Lederman & Co., LLC, dated October 15, 2013.
10.02   Amendment to Employment Agreement, between Tonix Pharmaceuticals Holding
        Corp. and Leland Gershell, dated October 15, 2013.
10.03   Amendment to Employment Agreement, between Tonix Pharmaceuticals Holding
        Corp. and Bruce Daugherty, dated October 15, 2013.

  Add TNXP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TNXP - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.